MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Psoriasis: Treatment and Pathogenesis
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,393 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,393 works in the cohort · of 4,299,418page 43 of 48

Labels cover 8 of 2,393 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,393 of 2,393 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study
Kim Papp, Joseph F. Merola, Alice B. Gottlieb, C.E.M. Griffiths, Kristina Harris, Nancy Cross +3 more
2019· article· en· SKIN The Journal of Cutaneous Medicine· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
aboutno affunlabeled
Psoriasis: skin and nails
Cheryl F. Rosen, Brian Kirby
2018· book· en· Oxford University Press eBooks· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Efficacité et tolérance du risankizumab chez les patients adultes atteints de psoriasis en plaques modéré à sévère avec atteintes palmo-plantaires non pustuleuses : variation du DLQI et obtention d’un score DLQI 0/1 dans l’étude de phase 3b IMMprint
M.G. Lebwohl, Michael Bukhalo, Linda Stein Gold, Michelle T. Pelle, B.P. Glick, Mar Llamas‐Velasco +6 more
2024· article· fr· Annales de Dermatologie et de Vénéréologie - FMC· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Efficacité et tolérance à long terme du risankizumab (RZB) dans le traitement du psoriasis en plaques modéré à sévère: résultats de l’étude d’extension en ouvert LIMMitless, analyse intermédiaire jusqu’à 5 ans de suivi
Kim Papp, Mark Lebwohl, L. Puig, Mamitaro Ohtsuki, Stefan Beissert, J. Liu +6 more
2023· article· fr· Annales de Dermatologie et de Vénéréologie - FMC· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Améliorations cliniquement significatives des critères-patient sous guselkumab chez les patients atteints de rhumatisme psoriasique actif en réponse inadéquate aux anti-TNF : résultats à un an d’une étude de phase 3b, randomisée, contrôlée (COSMOS)
Laure Gossec, Xenofon Baraliakos, James Galloway, Lars Erik Kristensen, V. Oke, Petros P. Sfikakis +4 more
2023· article· fr· Revue du Rhumatisme· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Considérations pour l’interprétation et la comparaison de l’efficacité à long terme des études portant sur le traitement du psoriasis modéré à sévère à l’aide d’agents biologiques
Richard G. Langley, Alexander Egeberg, M. Gooderham, Robert Bissonnette, J. Ringuet, Sunil Kalia +7 more
2024· article· fr· Annales de Dermatologie et de Vénéréologie - FMC· Immunology and Microbiology
machine prediction:candidate · metaresearchconsensus · metaresearch
0
citations
affunlabeled
Active Psoriasis Unassociated with Proteinuria
David Churchill, Nordau Kanigsberg, David J. Hollomby, John F. Seely
2008· article· en· ˜The œNephron journals/Nephron journals· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
afffundunlabeled
Reply
Lihi Eder, Xianwei Li, Richard J. Cook, Vinod Chandran, Cheryl F. Rosen, Dafna D. Gladman
2025· letter· en· Arthritis Care & Research· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
aboutno affunlabeled
Psoriasis in children
R Pinson, B Sotoodian, L Fiorillo
2016· article· en· DOAJ (DOAJ: Directory of Open Access Journals)· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
A Useful Clinical Tool for Psoriasis
Karina Nabieva, Ronald Vender
2021· letter· en· Journal of Cutaneous Medicine and Surgery· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations

How this was built: Screen · Findings · About